Skip to main content
NewslettersWatchlist

Hydreight Technologies Inc(NURS-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.250
Day High0.275
Open:0.275
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Hydreight Reports Record Topline(1) Revenue of $4.87M in Q1-2024 (YOY Increase of 33%)
GlobeNewswire
Victory Square Company Announces Access to Tirzepatide and GLP-1 Injections to its Weight Loss Portfolio
GlobeNewswire
Hydreight Technologies through its associated Medical network now offer Tirzepatide to Product Offering which also features GLP-1 Medications (Low-Cost Semaglutide), NAD+ and more
GlobeNewswire
Hydreight Achieves Record Revenue, Files Audited Financial Statements for Fiscal Year 2023
AI-generated - The Globe and Mail
Hydreight Technologies: Top 10 Undervalued Healthcare Providers & Services Industry Stocks (NURS)
GlobeNewswire
Hydreight Partners with American Frontline Nurses with a Network of Over 26,000 Nurses
GlobeNewswire
Hydreight Partners with Ola Digital Health, an Independent, National Pharmacy Network to Provide Health and Wellness Services in Store
GlobeNewswire
Hydreight Founder and CEO, Shane Madden, Joins Founding Member Board of the American IV Association
GlobeNewswire
Hydreight to Participate in the Maxim Group Healthcare IT Conference January 24 – 25, 2024
GlobeNewswire
Victory Square Portfolio Company Hydreight Provides Year-End Review on Significant Growth and Progress
GlobeNewswire
Hydreight Provides Year-End Review on Significant Growth and Progress
GlobeNewswire
Victory Square Portfolio Company Hydreight Adds Semaglutide to Product Offerings
GlobeNewswire
Hydreight Adds Semaglutide to Product Offerings
GlobeNewswire
Hydreight Expands White Label Solution with a New National Wellness Med Spa Franchise
GlobeNewswire
Hydreight Reports Record Revenue in Q3 2023
GlobeNewswire
Victory Square Portfolio Company Hydreight Named One of Canada’s Companies-to-Watch in Deloitte’s Technology Fast 50™ Program
GlobeNewswire
Hydreight Named One of Canada’s Companies-to-Watch in Deloitte’s Technology Fast 50™ Program
GlobeNewswire
Hydreight Launches NAD+ as Part of Robust Patient Service Offering
GlobeNewswire
Hydreight Provides Corporate Update Reflecting Significant Revenue Growth and Strong Organic Operational Growth
GlobeNewswire
Victory Square Technologies Reports 2023 Q2 Financial Results
GlobeNewswire
Hydreight Announces Q2 2023 Financial Highlights
GlobeNewswire
Hydreight Announces Nationwide Expansion of Doctor Network to Meet Demand Across All 50 US States
GlobeNewswire
Hydreight to Host Company Overview and Corporate Update Webinar on August 17, 2023 at 11 AM PT / 2PM ET
GlobeNewswire
VS Digital Health To Launch New Nurse Dispatch Service “MobileMedIV.com” Across the US
GlobeNewswire
Hydreight To Launch New Website Booking System And Nurse Dispatch Service Making IV Drip Therapy Bookings Faster And Easier
GlobeNewswire
Hydreight Provides Corporate Update Citing Tremendous Growth Along With New Features And Services
Baystreet
Stocks in play: Hydreight Technologies
Baystreet
Stocks in play: Victory Square Technologies

Profile

Hydreight Technologies Inc is a home healthcare and wellness platform that bridges the gap between provider compliance and patient convenience, empowering nurses, med spa technicians, and other licensed healthcare professionals. It delivers services independently, on its own terms, or adds mobile services to existing location-based operations. The platform includes a built-in, easy-to-use suite of fully-integrated tools for accounting, documentation, sales, inventory, booking, managing patient data, and more, Hydreight has a 503B pharmacy license and is a U.S. certified e-script and telemedicine provider that allows it to provide services in over 50 states.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.